Welcome to our dedicated page for National Resh SEC filings (Ticker: NRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for National Research Corporation (NRC Health, NASDAQ: NRC) provides direct access to the company’s official U.S. Securities and Exchange Commission documents, along with AI-powered summaries to help interpret them. As a Delaware corporation and public company, NRC files current reports, periodic reports, and other disclosures that describe its financial condition, operations, and governance.
Among the most relevant filings for NRC Health are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which present audited or reviewed financial statements, management’s discussion and analysis, and details about revenue, operating expenses, cash flows, and risk factors. Investors use these filings to understand trends in NRC Health’s healthcare experience management business, including subscription-based activity reflected in measures such as Total Recurring Contract Value (TRCV), and to see reconciliations for non-GAAP metrics like Adjusted EBITDA and Adjusted Net Income.
The company also files current reports on Form 8-K to announce material events. Recent 8-Ks reference press releases about quarterly financial and operating results and the appointment of an Executive Vice President and Chief Financial Officer, including a description of related compensation arrangements. These filings help readers track significant corporate developments between periodic reports.
On this page, AI-generated highlights summarize key points from lengthy filings, making it easier to locate information about earnings, capital allocation decisions such as dividends and share repurchases, and changes in leadership or governance. Users interested in executive roles, compensation structures, or other governance matters can review proxy-related disclosures when available, while those focused on trading activity can consult forms related to insider transactions, such as Form 4, when they are filed. Real-time updates from EDGAR ensure that new NRC Health filings appear here promptly, with plain-language explanations to support faster analysis.
National Research Corporation filed a current report to furnish a press release announcing its financial and operating results for the fourth quarter and full year ended December 31, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this report.
The company states that the information under the results and exhibits sections is being furnished, not filed, under securities laws. It also notes that the materials may include forward-looking statements, which are subject to risks and uncertainties described in its press releases and SEC filings.
National Research Corp's Executive Vice President and Chief Financial Officer, Shane R. Harrison, reported a stock transaction involving company common shares. On 12/29/2025, a Form 4 shows a disposition of 21,271 shares of Common Stock at a price of $18.66 per share under transaction code F. Following this transaction, Harrison is reported to beneficially own 150,729 shares of National Research Corp common stock, held directly.
National Research Corp executive David Burik, EVP of Strategic Insights, reported a grant of 100,000 shares of common stock on January 5, 2026. These are restricted shares issued at a price of $0.00 per share under the National Research Corporation 2025 Omnibus Incentive Plan. Following this award, Burik beneficially owns 100,000 shares directly.
The restricted shares will vest in three approximately equal installments on January 5, 2027, January 5, 2028, and January 5, 2029, subject to specified vesting, forfeiture, and termination provisions. This filing reflects equity-based compensation rather than an open-market purchase or sale.
National Research Corp executive files initial ownership report showing no holdings
National Research Corp executive David Burik, who serves as EVP, Strategic Insights, filed an initial ownership report on Form 3. The filing states in the explanation of responses that no securities are beneficially owned, and both the non-derivative and derivative securities tables are empty. The form is filed for one reporting person and confirms his role as an officer of the company rather than as a director or 10% owner.
National Research Corp Chairman and director Michael D. Hays reported an insider equity transaction. On January 5, 2026, he exercised an employee stock option to acquire 9,145 shares of common stock at $15.23 per share, increasing his directly held common stock to 20,154 shares after the transaction. The option covered 9,145 underlying shares and shows no remaining derivative balance.
The filing also reports 76,095 shares of common stock as indirectly owned by his spouse. Hays includes a footnote stating that he disclaims beneficial ownership of those indirectly held shares, clarifying how they are attributed for reporting purposes.
National Research Corp EVP and COO updates equity holdings through option exercise and share withholding. On 12/15/2025, the executive exercised employee stock options to acquire 12,346 shares of National Research Corp common stock at $15.23 per share. On the same date, 11,244 shares of common stock were disposed of in a transaction reported with code "F" at $17.64 per share, typically used for shares withheld to cover taxes or similar obligations. Following these transactions, the executive directly beneficially owns 140,518 shares of common stock and holds no remaining employee stock options from this grant.
National Research Corporation (NRC) reported Q3 2025 results. Revenue was $34.6 million versus $35.8 million a year ago, and net income was $4.1 million with diluted EPS of $0.18. Operating income was $7.7 million, producing a 22% operating margin. The effective tax rate rose to 34%.
Year to date, revenue totaled $102.2 million and operating income $17.9 million, with cash provided by operating activities of $19.3 million. NRC ended the quarter with cash of $2.2 million, $80.4 million outstanding on its Delayed Draw Term Loan at a floating rate of 6.63%, and full availability on a $30.0 million revolver. Total Recurring Contract Value was $141.7 million as of September 30, 2025. The company paid common dividends of $8.3 million and repurchased shares for $20.2 million in the first nine months. Effective September 29, 2025, Shane Harrison became Executive Vice President and Chief Financial Officer.
National Research Corp (NRC) reported an initial beneficial ownership statement (Form 3) for Executive Vice President Jason Russell Rau, effective 10/15/2025. The filing states that no securities are beneficially owned by the reporting person. The form was submitted as a single reporting person filing and executed via attorney-in-fact under a power of attorney.
National Research Corp (NRC) reported a director equity award on Form 4. On 10/17/2025, the reporting person received a Director Stock Option grant for 22,625 options at an exercise price of $11.61 per share. The award vests/becomes exercisable on 10/17/2025 and expires on 10/17/2035, with 22,625 derivative securities beneficially owned directly after the grant. The filing notes the grant was made under the Issuer’s 2025 Omnibus Incentive Plan for participating in two in-person meetings during 2025.
FAQ
What is the current stock price of National Resh (NRC)?
What is the market cap of National Resh (NRC)?
